Product Description
Ademetionine (S-adenosylmethionine; SAMe) is a ubiquitous metabolite present in all cells and biological fluids, and serves as a methyl donor in a multitude of different methylation reactions involving proteins, phospholipids, catecholamines and DNA. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15989609/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Brazil | Bulgaria | China | Colombia | Czech | Ecuador | India | Italy | Korea | Lithuania | Malaysia | Mexico | Peru | Philippines | Russia | Slovenia | Ukraine | United Arab Emirates | United Kingdom | Vietnam
Approved Indications: None
Company: VIATRIS & KG
Company Location: Europe
Company Founding Year: 2020
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Hong Kong, Italy, Korea, New Zealand, Thailand, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major
Phase 2: Chemical and Drug Induced Liver Injury|Colorectal Cancer|Hepatic Veno-Occlusive Disease|Hepatitis B, Chronic|Intestinal Diseases|Liver Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06258525 |
IIT2022-11-Gangi-SAMe | P2 |
Not yet recruiting |
Chemical and Drug Induced Liver Injury|Colorectal Cancer|Liver Cancer|Hepatic Veno-Occlusive Disease |
2028-08-01 |
12% |
2026-05-07 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
ACTRN12619001210167p |
2006-7041-83/hah | P2 |
Not yet recruiting |
Intestinal Diseases|Hepatitis B, Chronic |
2020-03-31 |
|||
2024-513019-29-00 |
MYL-1603N-3001 | P3 |
Recruiting |
Depressive Disorder, Major |
2027-01-31 |
2025-05-02 |
Treatments |
|
2024-513022-29-00 |
MYL-1603N-3002 | P3 |
Recruiting |
Depressive Disorder, Major |
2025-06-19 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/22/2025 |
News Article |
Nerve Freedom Reviews [Investigated Complaints] Nerve Alive Best Neuropathy Supplement for Nerve Pain Relief Naturally |
|
08/15/2024 |
News Article |
Pathos Expands Pipeline With Worldwide License of Phase 2-ready Brain-penetrant, PRMT5 Inhibitor |
|
09/26/2023 |
News Article |
The Future of AR Waveguide Market - Size, Valuation, and Growth Prospects by 2031 |
|
02/13/2023 |
News Article |
Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM) |